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ABSTRACT 
 One of the most urgent problems in the fields of medicine and agriculture is the 
decreasing effectiveness of antibiotics.  Once a miracle drug, antibiotics have recently become 
associated with the creation of antibiotic-resistant bacteria.  The main limitations of these 
treatments include lack of both adaptability and specificity.  To overcome these shortcomings of 
current antibiotic treatments, there has been a renewed interest in bacteriophage research.   
Bacteriophages are naturally-occurring viruses that lyse bacteria.  They are highly 
specific, with each bacteriophage type lysing a narrow range of bacteria strains.  Bacteriophages 
are also ubiquitous biological entities, populating environments where bacterial growth is 
supported.  Just as humans are exposed to bacteria in their daily lives, we are exposed to 
bacteriophages as well.   
To use bacteriophages in practical applications, they must be delivered to the site of an 
infection in a controlled-release system.  Two systems were studied to observe their support of 
bacteriophage lytic activity, as well as investigate the possibility of controlling bacteriophage 
release rates.  First, hydrogels were studied, using crosslinking and blending techniques to 
achieve a range of release profiles.  Second, polyanhydride microparticles were studied, 
evaluating release rates as a function of monomer chemistries.   
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CHAPTER 1: INTRODUCTION 
1.1 Bacteriophage Overview  
 In our environment, there exists an ubiquitous antibiotic entity that works silently to 
maintain microbial equilibrium: the bacteriophage.  A bacteriophage is a type of virus that 
infects a specific bacterium through its membrane and transfers viral DNA into the cell, either 
into or outside of the cell’s genome.  Eventually the infected bacterium will replicate hundreds of 
phages and undergo membrane rupture.   
 These viruses exist in soil, seawater, and any other environment that supports bacterial 
growth.  In fact, bacteriophages are the most abundant and diverse biological entity on earth [1].  
They are also remarkably effective: for nearly every known strain of bacteria, there exists a 
corresponding bacteriophage that can infect it [2].  Bacteriophages are thought to be responsible 
for between 10-80% of bacteria deaths in aquatic ecosystems [3].  As each environment varies in 
temperature, chemical composition, and microbiota, so too does the concentration of bacteria and 
its impact on the ecosystem [4].   
Figure 1.1 
Image of bacteriophage T4, obtained 
using transmission electron microscopy
100 nm 
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 The general structure of a bacteriophage is similar to that of a common virus, with 
genetic material encased in an icosahedral capsid.  Bacteriophages are made up almost entirely 
of protein and nucleic acid material, though the structures of different types of bacteriophages 
vary.  In these experiments, we mainly used the well-studied T4 and T7 bacteriophages, shown 
in Figures 1.1 and 1.2 [2], and these phages will be the focus of structure comparison.  We also 
briefly considered the phage φX174, which will be used for comparison when appropriate.  
Relatively complex bacteriophages, such as T4, feature a tail collar, tail core and sheath, base 
plate (or tail plate), tail pins, and six tail fibers.  The T4 phage, due to its long tail and many 
auxiliary structures, has a total length of 200 nanometers: a 100 nanometers capsid length and 
100 nanometers total tail length [2].  In contrast, the T7 phage is much simpler, with six tail 
fibers as its only auxiliary structure.  The T7 phage has a length of 50 nanometers and total tail 
length of 20 nanometers [5].  Despite the differences between phages T4 and T7, both are 
specific to Escherichia coli (E.coli) bacteria and undergo the infection process through similar 
means.  The phage φX174 contains no tail, and is also icosahedral in shape with a length of 25 
Figure 1.2 
Size and structure of bacteriophages T4, on the left; and T7, on the right. 
50 nm 
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nanometers [6].  Its infection process is different from that of T4 and T7 and will be used to 
illustrate the multiple possible infection mechanisms. 
1.2 Bacteriophage Biology  
 Bacteriophages are remarkable in that each bacteriophage type may only infect a specific 
bacterial strain.  Due to co-evolution of bacteriophages and bacteria, the viruses have adapted to 
the biochemical markers in the membrane of the target cell.  The process of co-evolution has 
given rise to both structures to facilitate infection (such as the tail) and alternative virus-
membrane binding requirements [1]. 
 To infect a bacterium, the bacteriophage must first adsorb onto the surface of the cell.  In 
phages with tail fibers, the fibers identify a high concentration of receptors on the membrane 
surface of the target cell, where the tail fibers act as a “ligand” for the receptors [7].  The 
interaction between the phage and bacterial membrane is often compared to a chemical reaction 
and is shown to occur in two steps: reversible adsorption, followed by irreversible fixation.  The 
reversible adsorption process follows first-order adsorption kinetics characterized by a phage 
adsorption constant [4], requiring physical contact between three of the six tail fibers and 
membrane receptor [2].   
 After adsorption, the phage binds irreversibly to a second receptor membrane, which has 
been identified as the heptose residue of the lipopolysaccharide, or LPS, inner core [1].  In phage 
T4, this irreversible binding occurs via a conformational change in the baseplate [2].  Phage T7, 
which does not contain a baseplate, contains tail-related proteins inside the capsid that serve as a 
core to guide DNA transfer.  The viral DNA from phage T7 is transferred more slowly than that 
of T4, and the transfer process is dependent on the host cell RNA polymerase to act as a 
molecular motor [1].  The bacteriophage tail guides the viral nucleic acid material across the 
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bacterial membrane into the cell.  Phages with contractile sheaths further ensure the transfer of 
viral nucleic acid material by shortening the distance between the viral head and cell interior.   
 Once the viral DNA has been introduced to the cell interior, transcription begins upon 
contact with the host RNA polymerase.  These first-phase genes are known as immediate early 
genes.  Transcription of these genes results in molecules that serve to protect the viral DNA and 
further tailor the host cell’s biology toward phage survival by degrading host DNA or destroying 
enzymes and other proteins that impede the production of new bacteriophages [1]. The next 
phase of viral DNA is known as the middle genes, which codes for new viral DNA.  Lastly, the 
final phase of viral DNA is the late genes.  These genes, when transcribed, produce the proteins 
necessary for production of new phage components to encase and transport the newly-made viral 
DNA [1].  After phage production is complete, the viral DNA will initiate a rupture of the 
cellular membrane. 
 Depending on the type of phage, membrane rupture can occur via the lytic cycle or the 
lysogenic cycle.  The phages T4 and T7, as well as φX174, undergo the lytic cycle, as illustrated 
in Figure 1.3 [1].  However, the process differs between phages with double-stranded DNA, such 
as T4 and T7, and those with single-stranded DNA, such as φX174.  In double-stranded DNA 
phages, the viral genetic code produces the enzyme endolysin.  To trigger membrane rupture, 
endolysin must interact with the membrane protein holin, which is also encoded in the viral 
DNA.   
 The holin production is the limiting factor in the lytic process, and the timing of its 
production can be controlled via production of holin inhibitors coded in viral genes.  The delay 
in holin production allows time for the immediate early, middle, and late phase viral DNA to be 
transcribed.  Holin production can also depend on growth conditions of the new viruses [1].  
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When between 100 and 300 daughter viruses are produced, holin proteins are allowed to 
accumulate and lysis can begin.  The holin proteins then solubilize the bacterial membrane to 
such a degree that the endolysin enzyme is able to break down the bacterial cell walls[8]. 
 To compare, the lytic process of a single-stranded DNA bacteriophage is characterized by 
transcription of viral DNA to produce centromere-associated protein E, or CENPE.  This protein 
then inhibits the membrane enzyme phosphor-MurNAc-pentapeptide translocase, or MraY.  The 
MraY enzymes catalyze the synthesis or murein, which makes up a crosslinked mesh outside of 
the bacterial membrane.  After murein inhibition, the bacterial membrane is weakened, and 
CENPE proteins oligomerize into a trans-membrane tunnel [9].  After sufficient membrane 
breakdown, daughter bacteriophages escape the cell.  The phage φX174, a single-stranded DNA 
phage, was briefly considered for study, but was ruled out due to its instability in organic 
solvents. 
 The term “virulent” is generally applied to bacteriophages that undergo the lytic cycle, as 
compared to “temperate” for lysogenic bacteriophages.  Since the lytic cycle is more rapid than 
lysogeny, a virulent phage population is expected to have a more immediate effect on its target 
bacterial population.  It is important to note that the rate of bacteriophage population change is 
independent of peak phage population, which is the determining factor for total elimination of 
Figure 1.3 
Cartoon of infection by a lytic bacteriophage, from adsorption 
to burst. 
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the target bacteria strain [4].  This is to say, virulent bacteriophages are not intrinsically more 
effective than temperate bacteriophages, but they do lyse bacteria more quickly. 
1.3 History of Bacteriophage Use 
 Before bacteriophages were formally identified, their bacteriocidal effects had been 
observed in microbiology work.  One of the first references to bacteriophages is thought to be a 
work by Ernest Hankin in 1896.  While studying cholera microbes in the Ganges and Jumma 
rivers, he observed a bacteriocidal property in filtered river water [10].  After the turn of the 
century, two independent researchers identified bacteriophages almost simultaneously.  
Frederick Twort of the United Kingdom and Felix d’Herelle of France, in 1915 and 1917 
respectively, demonstrated the lytic activity of bacteriophages.  By 1921, d’Herelle had found 
success in treating chickens with bacteriophages against avian typhosis.  He expanded his 
research to field work in rural France, treating flocks of chickens in areas where avian typhosis 
was an epidemic.  He found that flocks that had received bacteriophage had fared much better: 
fewer chickens died, the duration of the illness was shortened, and the possibility of secondary 
infection was minimized [1].   
 D’Herelle went on to successfully immunize himself, his coworkers, and his family 
against dysentery by administering injections of an anti-Shinga bacteriophage suspension.  In 
1925, d’Herelle treated four bubonic plague patients by injecting anti-plague bacteriophage into 
the infected lymph nodes, or buboes, of the patients.  As d’Herelle’s successes became more 
well-known, he traveled to the Haffkine Institute in Bombay, India to develop a treatment for 
cholera epidemics.  He developed bacteriophage therapy regimens both as a preventative 
measure as well as a treatment for those already suffering with the disease [1].  By the late-
1920s, bacteriophage therapy was a popular area for research.  In addition to d’Herelle’s 
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treatments, typhoid fever, Bacillus anthracis and Staphylococcus had been successfully treated 
with bacteriophage therapy [10].   Therapy trials were administered using both oral and injected 
doses, to great success. 
 In the same time frame, bacteriocidal activity of mold and fungi was also being observed, 
eventually leading to Alexander Fleming’s discovery of penicillin in 1928.  After his discovery, 
bacteriophage research became stagnant in North America and Western Europe due to the 
presence of both positive and negative results seen in literature regarding bacteriophage therapy.  
However, Eastern Europe established a research institute for bacteriophage study in 1923 in 
Tbilisi, Georgia which continued its bacteriophage work.  The findings were published in 
Russian scientific journals, stimulating interest in bacteriophage therapy in Russia and Poland 
[11]. 
 In the 1940s bacteriophages regained popularity, when Max Delbrück spearheaded a 
study in bacteriophage genetics, specifically the phages lambda and T4, to investigate the lysis 
mechanism of the viruses.  In the course of his research, he demonstrated that a bacterium was 
lysed by one virus type, highlighting the specificity of bacteriophages.  To simplify his research, 
Delbruck focused on T-series phages and their lysis of the B strain of E.coli.  His research led to 
T-series, which includes bacteriophages T1 through T7, being the most well-studied 
bacteriophages [2].  Bacteriophages that are classified as T-even (T2, T4, and T6) were studied 
first because the viral DNA of these entities contain a novel base: 5-hydroxymethylcytosine, 
which clearly differentiated viral DNA from host cell DNA in early experiments [1].  
Unfortunately, the renewed interest in bacteriophages was short-lived due to World War II, at 
which time antibiotics saw a surge in popularity.  Such levels of interest in bacteriophages did 
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not return until 1967, when lambda phages were used to isolate lambda repressor, a DNA-
binding protein [11].  
1.4 Bacteriophages in Biological Systems 
 With the recent rise of environmental research, the ubiquity of phages has become clear: 
bacteriophages “are by far the most numerous biological entity on our planet, [10]” with 
concentrated populations in bacteria-rich environments such as soil, oceans, and wastewater.  It 
is estimated that bacteriophages outnumber cellular organisms ten to one.  While it is commonly 
known that the human body’s cells are outnumbered by colonizing bacteria, those bacteria are in 
turn outnumbered 100 to one by colonizing bacteriophages [10].   
 Humans  and animals are exposed to bacteriophages throughout life, so bacteriophage 
treatments are generally harmless when proper bacteriophage preparations are administered [1].  
Healthy humans have low levels of bacteriophages present in the digestive tract, which are 
thought to have little impact on the intestinal microbiota.  In patients with internal illness, fecal 
phage titers increase, as do the diversity of phages present.  The magnitude of phage titers is also 
observed to have a positive correlation with the severity of the disease [3].  Similarly, in canine 
populations, fecal bacteriophage presence is dependent on living conditions.  Dogs that are kept 
in a clean environment as house pets show very low levels of bacteriophage, while dogs living in 
kennels show higher bacteriophage presence [3].  The presence of bacteriophages does not cause 
the disease, but rather the increased presence of bacteria (i.e. severity of the disease) causes an 
increase in bacteriophage lysis and multiplication. 
1.4.1 Bacteriophages in Medicine 
 In the 1960s through the 1980s, large-scale bacteriophage studies were conducted in 
Eastern Europe to evaluate effects of bacteriophage therapy on antibiotic-resistant bacteria 
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infections.  Soviet scientists tended to focus on prophylactic bacteriophage therapy, while Polish 
scientists tended to apply bacteriophages to patients with pre-existing infections.   
 One of the most prominent bacteriophage studies conducted in the Soviet republic of 
Georgia was to use bacteriophages as prophylaxis against Shigella, or dysentery.  The study was 
conducted on over 30,769 children, where 17,044 received a weekly oral dose of bacteriophages, 
and 13,725 received placebo treatment as a negative control.  The children received weekly visits 
from scientists, who administered phage and performed a health evaluation.  After a 109-day 
period, fecal samples were tested for presence of Shigella bacteria.  Clinical diagnosis based on 
weekly health evaluation found that dysentery rates were 6.7 and 1.76 cases per 1,000 children, 
for placebo and bacteriophage-treated groups respectively.  Diagnoses based on fecal bacteria 
culture indicated that dysentery rates were 1.82 and 0.7 cases per 1,000 children, for placebo and 
bacteriophage-treated groups respectively.  The bacterial culture also tested for unspecified 
diarrhea-causing bacterial infections, which yielded similar results: presence of diarrhea-causing 
bacteria showed a 2.3-fold reduction between the placebo and bacteriophage-treated group [12]. 
 In Poland, scientists studied several pathogens (Staphylococcus, Pseudomonas, 
Escherichia, Klebsiella, and Salmonella) in order to find a potent corresponding bacteriophage.  
They then applied this knowledge to a large study with 518 patients with cases of antibiotic-
resistant infection.  The patients received bacteriophage therapy one of three ways: orally (with a 
baking soda to neutralize stomach pH), locally (with wound dressings or application in the 
pleural or peritoneal cavities) or via drops applied to the nasal mucosa, eye, or middle ear.  
Throughout the study, the bacterial infection was monitored for bacterial resistance against 
bacteriophage infection.  If resistance was detected, the patients received treatment with a new 
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type of bacteriophage.  The treatment was found to completely eradicate the infection in 94% of 
patients [12].  
 Other successful studies conducted in the Soviet Union included treatments for 
staphylococcal infections in the lung, eye infections, neonatal sepsis, urinary tract infections, and 
surgical wound infection.  In Poland, successful applications of bacteriophage therapy included 
treatments for cerebrospinal meningitis in a newborn, various chronic bacterial infections, and 
stabilization of tumor necrosis factor alpha (TNF-α) levels in blood serum. However, many of 
these studies do not hold up to the rigor of today’s scientific standards: many studies lack 
negative controls, while some studies do not report information on the number of subjects 
receiving each type of treatment [12].   
1.4.2 Bacteriophages in Agriculture 
 Bacteriophages have great potential in agricultural applications in addition to medicine.  
As antibiotics fall out of favor as a prophylactic treatment for livestock, bacteriophage therapy 
has shown great potential to reduce infections in both animals and plants, resulting in better 
protection against foodborne contamination [1]. 
 As discussed above, Felix d’Herelle successfully used bacteriophages to treat avian 
typhosis in chicken flocks.  Subsequent experiments performed by other scientists expanded the 
scope of study to other animals, which showed positive outcomes as well as negative outcomes.  
This can be attributed to variation in animal model, target bacteria, and bacteriophage potency.  
In a study of salmonella treatment, chicken and mouse animal models were used with 
bacteriophages did not show lytic activity in vitro.  In this case, the experiment failed to show 
protection against salmonella, leading to the conclusion that failed in vitro tests were a good 
predictor of failed phage performance in vivo [1].   
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 Recent veterinary experiments have shown that bacteriophage treatments in animals with 
doses as low as 102 PFU have the capacity to prevent infection when administered 
simultaneously with the infecting bacteria.  However, a low dosage is effective primarily as a 
prophylactic measure, as a 102 PFU dosage is less effective when administered after the infection 
has been introduced [3]. 
 Based on these initial findings, there has been interest in administering bacteriophages to 
pigs for the treatment of Salmonella typhimurium, which is the bacteria that causes salmonellosis 
in humans.  Effective treatment and containment of Salmonella would decrease risk of foodborne 
illnesses greatly.  Due to livestock living conditions, Salmonella was found to disseminate 
rapidly among pigs, with an increase in infection rates between farm and lairage, and again 
between lairage to slaughterhouse.   In one phage study, a group of pigs were experimentally 
infected with Salmonella, then treated with bacteriophage against Salmonella three hours later.  
It was found that the pigs’ tonsil and cecum tissues harbored the most Salmonella cells, resulting 
in the bacteriophage treatment being targeted to these areas.  The treatment did not eliminate the 
Salmonella infection in its entirety, but it did reduce the number of bacterial cells in the target 
area and significantly decreased the risk of spreading the disease.  However, the intestinal 
contents of the pigs still did show a considerable amount of Salmonella cells, which indicates 
that the porcine intestine may reduce phage propagation and activity [13]. 
1.4.3 Bacteriophage as an Alternative to Antibiotics 
 Bacterial infections in humans, animals, and plants are currently controlled with 
antibiotics.  Antibiotics are produced most commonly by soil bacteria and fungi, though the 
antibiotic molecules’ function in nature is still in dispute [11].  Based on the antibiotic synthesis 
processes found in nature, pharmaceutical labs have implemented multistep procedures to 
12 
 
produce synthetic antibiotics.  Most of the antibiotics produced today are based on either a 
natural compound, or a by-product of an attempt to synthesize a natural compound.  However, in 
the past 25 years, there has been little impetus for pharmaceutical labs to seek out new antibiotic 
compounds from natural sources because of the success of the current formulations.  In recent 
years, antibiotic resistance has increased the demand for new forms of antibiotics, changes in 
current formulations to overcome resistance mechanisms in bacteria, as well as alternative 
treatments altogether [14].  Unfortunately, this process may take several years [12].  This is 
because antibiotic formulations have varying degrees of effectiveness, and relatively few 
formulations are safe for humans, as compared to the vast amount of antibiotic chemicals that 
exist in nature.  Furthermore, approval of new antibiotic drugs adds additional years between 
discovery and general use. 
 When treating infections with bacteriophage therapy, it is important to note the expected 
differences as compared to commonly-used antibiotic treatment.  Firstly, antibiotic treatment can 
target a broad range of bacteria whereas bacteriophages are highly specific.  A bacteriophage 
treatment would be best suited to an infection in tissue inhabited by both healthy and pathogenic 
bacteria, where the widespread destructive power of antibiotic therapy may produce undesirable 
complications, such as in the digestive tract.  A bacteriophage treatment would be more difficult 
in the case of infection by several different strains of bacteria [1].  In this case, the target bacteria 
would need to be identified quickly and the patient would receive a cocktail of bacteriophages.   
 In human studies, treatments of certain infections using lytic phages, such as 
Staphylococcus bacteria, have been shown to be more effective than their antibiotic counterparts.  
In a study of staphylococcus infection in the lung, intravenous bacteriophage, oral bacteriophage, 
and oral antibiotic treatments were compared.  The intravenous bacteriophage treatment 
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eradicated the infection in 95% of patients, and oral bacteriophage treatment showed complete 
recovery in 82% of patients, as compared with 64% of patients in the antibiotic group [12]. In 
animal studies, a bacteriophage preparation that has been carefully selected for the target bacteria 
has also been shown to be as effective as an antibiotic regimen, if not more so [1].   
 Early Eastern European studies have shown that bacteriophages are generally a safer 
treatment than antibiotics.  Antibiotic treatments often eradicate bacteria nonspecifically, and 
such treatments are liable to cause intestinal disorders as a result of disruption of digestive 
microbiota, allergies, and secondary (e.g. yeast) infections [12].  In contrast, no studies reported 
serious side effects of bacteriophage treatments, likely because of the vast amount of 
bacteriophages that patients encounter through normal daily activity.  To ensure that 
bacteriophages do not mount an immune response, Polish scientist Stefan Slopek analyzed 
antibody titers during a study of treatment for staphylococcal bacteria.  Of the 57 patients 
participating in the study, 44 had no measurable antibodies, while 8 patients had a titer under 
1:40, and two patients had titers of 1:320-1280.  Slopek concluded that bacteriophage 
immunogenicity did not interfere with antibacterial processes [15].  Minor side effects of 
bacteriophage treatment are thought to be caused by endotoxins released by the lysed target 
bacterium, though the free endotoxins are present in any antibiotic treatment.   
 Along the same vein, the pharmacology of bacteriophages differ from antibiotic 
treatment.  Since antibiotics are non-living molecules, they must either be targeted directly at the 
infection site (which is often an internal organ), or must be administered via a systemic, or body-
wide, oral or injected dose.  Bioavailability of the antibiotic is therefore dependent on absorption, 
metabolism, and degradation.  To overcome these barriers, a relatively high dose of antibiotic is 
necessary to maintain minimum effectiveness [16]. 
14 
 
 Bacteriophages also face the same barriers.  However, because of the body’s familiarity 
with bacteriophages, a relatively high dose of bacteriophages is not harmful to digestion or other 
bodily functions.  Once bacteriophages reach the site of infection, the viruses proliferate upon 
lysis of target bacteria.  In this way, the virulent effect increases exponentially and reduces the 
need for frequent doses [12].  In a mouse study on the bioavailability of bacteriophage, the 
bacteriophage was removed from the mouse’s bloodstream after 48 hours, but a high titer 
remained in the mouse’s spleen [15]. 
 As mentioned above, antibiotic molecules are static formulations.  Engineering new, 
effective antibiotics can be a time-consuming process.  In contrast, bacteriophages have a history 
of co-evolution with bacteria, a process that can be replicated in lab by exposing phage-resistant 
bacteria to other types of phages.  When exposed to a high number of diverse phages, there is a 
high chance of finding a new treatment, whether by phage tail fiber adaptation or a separate 
infecting phage altogether. 
1.5 Difficulties with Bacteriophage Treatment 
 Bacteriophages are always found in environments that support growth of bacteria.  As a 
result, bacteriophages and bacteria have co-evolved with one another.  Bacterial mutations may 
improve immunity to infections by altering certain membrane receptors, or removing them 
altogether.  This immunity is generally temporary, as the mutated cell becomes susceptible to 
other bacteriophages that target different types of membrane receptors.   
 In the event of receptor alteration, bacteriophages can often adapt tail fibers to 
compensate for the change and still complete the adsorption process.  For example, the T4 phage 
is able to bind to a lipopolysaccharide specific to the B strain of E.coli, as well as the OmpC 
membrane protein found in the K strain, and the OmpF protein.  Interestingly, mutation in cells 
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occurs more easily than counter-mutation in viruses.  In this case, the bacteriophages rely on 
their sheer numbers in order to maintain microbial equilibrium [1].  However, anti-bacteriophage 
mutations are not always beneficial: deletion of membrane proteins may protect from 
bacteriophage infection, but may also prove detrimental to the cell’s survival.  The receptors 
targeted by bacteriophages are often necessary for the cell’s survival.  Loss of these proteins may 
lead to a weakened physiological state or loss of important functions in the cell [1]. 
 Due to the ubiquity of both bacteria and bacteriophages, regional and individually-hosted 
bacteriophages may affect research efforts.  It is possible that co-evolution can favor the bacteria 
rather than the bacteriophage, due to a higher degree of adaptability in a particular cell than the 
corresponding virus.  For example, a 2009 cholera outbreak in Zimbabwe spurred research into 
bacteriophages against the cholera microbe, also called vibriophages.  However, bacteriophage 
treatment was hindered by the fact that the vibriophage populations of Zimbabwe had affected 
evolution of the cholera bacteria by significantly altering serotype prevalences found on the cell 
membrane [17].  Bacteria and bacteriophages exist in a balance in nature, and if relatively few 
new phages are added to an environment, the bacteria may resist bacteriophage lysis over time.  
However, intervention of new bacteriophages to a bacteria population can counteract this effect, 
targeting alternative membrane proteins in the bacteria. 
 Lastly, bacteriophage therapy suffers from the perception of a lack of credibility because 
of negative results reported by several early studies.  Critics of bacteriophage therapy cite the 
narrow bacterial host range as a drawback because early studies did not use bacteriophage 
cocktails to compensate for anti-bacteriophage mutations.  In addition, many early bacteriophage 
treatments were ineffective or caused various side effects.  Scientists would often treat infections 
with bacteriophages intermixed with lysates (including endotoxins) from recently-burst host 
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bacteria, which can be responsible for side effects.  Very early scientists also did not distinguish 
between lytic and lysogenic viruses when developing treatments, and some conducted studies 
using the slower, less-effective lysogenic class of bacteriophages, producing negative results 
[12]. 
 Commercially-available bacteriophage stocks only reinforced the lack of credibility.  
Early bacteriophage treatments also contained phenol and merthioloate for sterility and stability, 
as was standard practice for vaccines, which resulted in inactivation of bacteriophages [18].  
Many pharmaceutical companies advertised stocks containing over 100 separate types of 
bacteriophages to treat many different infections, but these did not hold up to scrutiny by 
scientist Max Delbrück.  He found that the manufacturers did not grow phage types separately, 
but rather combined them before exposing the phage cocktail to a cycle of infection and phage 
growth.  Over many such passages, he found that the final phage stock contained only one type: 
T7 phage, which is specific to certain strains of E.coli [18].  By the time scientists learned more 
about bacteriophages, antibiotics had risen in popularity and bacteriophage therapy was no 
longer a research priority. 
1.6 Bacteriophage Delivery 
 In order to maximize effectiveness of bacteriophage treatment, polymers can be used as a 
vehicle to reach the site of infection in either humans or livestock animals.  Currently, drug 
treatments have been successfully delivered both orally and nasally.  In this study, the 
aforementioned vectors will be applied to bacteriophage delivery and support. 
1.6.1 Oral Delivery 
 Oral drug delivery systems are popular because of their ease of use for both medical 
professionals and patients.  Furthermore, controlled-release oral delivery provides a consistent 
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drug delivery over time, reducing the frequency of administration.  In controlled release systems, 
drug is released under certain conditions, including osmosis, pH, and other physiological factors 
[19]. 
 In the digestive tract, drugs are absorbed through the intestinal lumen.  Absorption of 
drugs can be hindered by intestinal pH and enzymatic activity in the lumen, as well as structural 
barriers like the mucous layer.  The epithelial layer, which is folded into the villi, consists of 
strongly-bound cells, such only very small, polar drug molecules can pass through the tight 
junction.  Therefore, most drugs must be absorbed by the epithelial cells in order to reach the 
bloodstream [20].  Large, polar drugs rely on the concentration gradient to aid diffusion into the 
epithelial cells.  Drugs with poor water solubility require surfactants, prodrugs, or other additives 
for absorption [21]. 
Interestingly, highly water-soluble drugs can also pose difficulties in controlled-release 
systems.  Such drugs demonstrated first-order release kinetics, characterized by a large initial 
burst of drug with subsequent low release levels.  Since water-soluble drugs are easily absorbed 
by epithelial cells, first-order kinetics can cause a very high amount of drug to enter the 
bloodstream in a short amount of time.  Ideal drugs, with average water solubility, show release 
closer to the desired zero-order release kinetics, which demonstrates consistent release over time 
[19]. 
Hydrogels, which consist of a stable network of crosslinked polymers, are often used in 
drug delivery applications.  Water-soluble drugs can easily be distributed throughout the gel, 
which generally consists of about 95% water.  While hydrogels are initially stable in water, they 
are prone to swelling and eventual degradation, which causes release of drug.  The chemistry of 
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hydrogels can be altered to reflect a desired rate of degradation, however by-products must be 
assessed to determine risk of inflammatory response [22]. 
1.6.2 Nasal Delivery 
 Drug delivery via nasal sprays and particles originally began as a treatment for infections 
and allergies in the nasal pathway.  More recently, there has been success with introducing 
systemic drugs via nasal delivery, especially when an immediate effect is necessary.  Systemic 
drug circulation is found to be effective for drugs that are difficult to inject or are poorly 
absorbed orally [23] using molecules with low molecular weight, including proteins, that would 
otherwise be difficult to use in injected treatments, as they are prone to metabolism by the host 
[24]. 
 The absorption of nasal drugs depends on the permeability of the nasal mucosa, which 
depends on the polarity of the drug.  Nonpolar drugs have been shown to absorb particularly well 
via nasal delivery, showing bioavailability near 80%.  This is because nonpolar drugs are 
absorbed in a transcellular process through passive diffusion or active transport through channels 
across the membrane.  Polar drugs, by contrast, show a much lower permeability and less 
bioavailability, near 10%.  The molecular weight of polar drugs can affect absorption as well.  
Drugs with low molecular weights (below 1,000 Da) are able to follow a paracellular route 
through the tight junctions between cells.  This route is not efficient for transport of drugs with 
high molecular weights, which must be transported in small amounts via an endocytotic transport 
process, wherein the drug is engulfed by the cell membrane into a vesicle.  If a drug is not 
absorbed within 15 to 20 minutes, the excess will be removed by mucociliary clearance [24].   
To promote absorption of a polar drug, chemicals like surfactants or bile salts can be used 
as enhancer agents.  The enhancer agents work through one of several methods.  Some alter the 
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phospholipid bilayer of epithelial cells, and others strip off the outer mucosa layer entirely.  
Others alter the tight junctions between surface cells, which may include acting as an enzyme 
inhibitor [24].  While many of these additives showed success in animal studies by greatly 
increasing drug bioavailability, absorption by animal mucosal tissues was positively correlated 
with damage from the additives [23].  Similarly, the success is less pronounced in human studies 
than animal because of the irritation of the mucosa layer.  Some gentler additives, like 
cyclodextrins and chitosan, enhanced absorption enough to justify their mucosal irritation [24]. 
 Bacteriophages against respiratory-pathway diseases are good candidates for nasal 
delivery.  In a patient with a pre-existing infection in the lung, a nasal bacteriophage dose would 
act as an immediate treatment because it would not need to travel systemically [24].  However, 
bacteriophages can be described as a protein-based particle of high molecular weight.  In these 
experiments, polyanhydride microparticles are used as a nonpolar encapsulation method for 
bacteriophages, promoting the transport of bacteriophages across the nasal mucosa. 
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CHAPTER 2: VISUALIZING BACTERIOPHAGE ACTIVITY 
2.1 Introduction 
Bacteriophage activity is most commonly evaluated using the agar overlay method, 
wherein a layer of top agar and indicator bacteria are spread over a layer of base agar.  The 
bacteriophages to be tested are introduced on top of the agar, at which time they lyse indicator 
bacteria during an incubation period.  The purpose of the base agar is to provide nutrients for the 
bacteria.  The top agar, because of its lower volume, contains fewer nutrients.  Instead, its 
purpose is to create an even bacteria lawn.  The mobility of the bacteriophages and the 
subsequent cleared area is limited by the concentration in the top agar, so the 0.5% agar powder 
is held constant.  This method is used in our experiments, and is described in more detail in the 
Experimental section of this chapter. 
 While the agar overlay method is most commonly used, it is not the only method of 
measuring bacteriophage activity.  For scientists who wish to determine the host range of a 
bacterium, a spot test method is used.  In this case, the indicator bacteria is replaced by a 
suspension of multiple host bacteria.  The bacteriophages are plated (“spotted”) on the top agar, 
then incubated [1].  The host range can be visualized by the size of the plaque, though complete 
clearing within the drop area is not automatically a positive result.  In some cases, very high 
bacteriophage concentrations can cause “lysis-from-without,” wherein the sheer number of 
bacteriophages overwhelm a cell’s ability to synthesize proteins, resulting in cell death [2].  To 
prevent false positive results, the bacteriophage suspension is plated in serial dilutions.  An 
example of serial dilutions atop a bacteria-agar overlay is shown in Figure 2.1.  
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In this experiment, we used the agar overlay method to evaluate the activity of T4 
bacteriophage against a K12 E.coli lawn.  The T4 bacteriophage infects K12 E.coli by binding to 
the lipopolysaccharide, or LPS, a receptor protein found in the outer cell membrane.  The 
interaction is a two-part phenomenon, as the LPS requires an interaction with protein Ib before 
acting as a receptor for T4 [7].   
 
 Bacteriophages may also be evaluated by microscopy.  Transmission electron microscopy 
(TEM) is an option for obtaining an image of the viruses.  The size and shape of the capsid is 
apparent under TEM imaging, as well as the presence of tails and tail fibers.  Historically, 
electron microscopy has been used to image viruses since the 1940s when the German scientist 
Helmut Ruska observed the bacteriophage-induced lysis of enterobacteria and enterococci.  
Since then, the TEM has been useful in classifying novel bacteriophages using existing 
bacteriophage families as a comparison [3].  An example of TEM imaging of bacteriophage 
activity is seen in Figure 2.2 [4]. 
Figure 2.1 
Dilution of T4 bacteriophage plated using the overlay 
method on a lawn of K12 E.coli.  The darker area 
indicates clearing of bacteria.  The scale bar indicates 1.3 
cm. 
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 As biological entities primarily made up of proteins, bacteriophages may also be detected 
by fluorescent microscopy.  The capsid contains the small outer capsid protein, which is used as 
an attachment site for a marker protein such as green fluorescent protein.  This is a useful 
technique for detecting encapsulated bacteriophages, or detecting the presence of the 
corresponding target bacteria under a fluorescence microscope [5].  An example of fluorescent 
imaging of bacteriophages is shown in Figure 2.3 [6]. 
2.2 Experimental 
 In this experiment, we visualized the effect of T4 bacteriophage on the K12 strain of 
E.coli.  The T4 bacteriophages were purchased from ATCC in freeze-dried form.  The K12 
E.coli were also purchased from ATCC as a freeze-dried pellet. 
Our experiments use K12 E.coli as the indicator bacteria.  E.coli is the most thoroughly-
studied bacterium and has been historically used in microbiology and genetics work.  The 
Figure 2.3 
A plaque created by λ bacteriophage is shown in 
epifluroescence illumination.  The scale bar 
denotes 150 μm. 
Figure 2.2 
TEM imaging of T4 bacteriophages. 
The image on the left shows a bacteriophage attached to the cell 
membrane, with a densely-packed capsid.  The image on the right 
shows a bacteriophage attached to the cell membrane with a hollow 
core after DNA injection through the membrane. 
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bacteria require as few as 8 hours to grow the full lawn required for bacteriophage indication.  
While the K12 strain is nonpathogenic, it can be used as a model for E.coli O157:H7, which is 
responsible for foodborne illness. 
2.2.1 Method for Bacteriophage and Bacteria Stocks 
 Preparation of stocks and other subsequent measurements were performed on Miller LB 
agar plates.  The base agar was prepared by mixing Miller LB media with 1.5% agar powder.  
The solution was autoclaved and 20 ml of liquid agar was measured into each plate.  The agar 
was allowed to set, after which the plates were stored at 4°C for up to two months.  The top agar 
was prepared by mixing Miller LB media with 0.5% agar powder.  The liquid agar was 
aliquotted into small bottles and autoclaved.  After autoclaving, one bottle was kept in a 50°C 
water bath and the others were stored at 4°C and solidified.  To prepare the solidified agar for 
use as top agar, the bottle was boiled in a hot water bath until the agar melted.  The agar was 
melted thoroughly to prevent microcrystals, which appear as lumps when the top agar is poured 
and can affect bacteriophage activity [1].  The melted top agar was cooled to 50°C before plating 
so that the indicator bacteria would not undergo heat shock. 
The K12 E.coli master stock, stored at -80°C, was used to spread a smear plate on Miller 
LB base agar (1.5% agar).  The plate was then inverted and incubated at 37°C overnight.  After 
the growth cycle, colonies of K12 E.coli were evident.  Each colony was assumed to be  
genetically uniform.  A general-use stock of E.coli was made by brushing up one colony with a 
pipette tip, then suspending the bacteria in 5 ml of Miller LB media.  The stock was incubated 
under shaking at 37°C overnight.  All subsequent stocks were grown with one colony from the 
smear plate.  Each grown stock produced full bacteria lawns for seven days, after which the stock 
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began to produce lawns with spots of clearing.  The smear plate was replaced after 
approximately two months. 
To make a T4 stock, the freeze-dried bacteriophages were suspended in Miller LB media, 
then serial dilutions were made with Miller LB media as the diluent.  We first allowed Miller LB 
agar plates to come to room temperature.  To these, we poured Miller LB top agar (0.5% w/v 
agar) mixed with 2% v/v K12 E.coli stock on top of the base agar.  The top agar was allowed to 
set.  The diluted bacteriophage solution was plated by dropping 5μl aliquots on the agar. The 
solution drops were allowed to dry.  The plate was then inverted and placed into a 37°C 
incubator for 18 hours.  After incubation, bacteriophage clearings called “plaques” were present 
on the bacteria lawn. 
Each bacteriophage plaque is considered to be genetically uniform, so one plaque was 
selected for amplification.  The plaque was brushed up by a sterile pipette tip, and stirred into a 
microcentrifuge tube containing 200 μl lambda buffer.  The bacteriophage-buffer solution was 
incubated at room temperature for 2 hours, after which it was applied to a K12 E.coli Petri dish 
as described above.  The dish was incubated overnight, after which a large percentage of the 
plate showed clearing of bacteria. 
We then added 10 ml of lambda buffer to the agar plate and allowed it to sit for 5 
minutes, which loosened the top agar.  The top agar was scraped off with a sterile L-spreader and 
placed into a 50 ml centrifuge tube.   We added 10 ml of chloroform to the mixture and mixed 
vigorously.  The mixture was centrifuged down, leaving separate chloroform, agar gel, and 
aqueous phases.  The aqueous phase, which contained bacteriophages, was skimmed off and run 
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through a 0.45 μm-pore filter to remove all remaining agar.  The final solution was then diluted 
to calculate concentration. 
2.2.2 Bacteriophage Concentration and Activity 
To find the concentration of bacteriophage suspended in a prepared stock, the stock was 
serially diluted by one tenth into lambda buffer.  The solutions were plated by 5 μl aliquots onto 
a bacteria lawn as described above.  The plate was then inverted and incubated at 37°C 
overnight.  After incubation, a countable dilution was found.  To be countable, the dilution had to 
show between three and 30 small, distinct plaques.  The formula for determining concentration is 
as follows: 
ܥ݋݊ܿ݁݊ݐݎܽݐ݅݋݊	 ൤ܲܨܷ݈݉ ൨ ൌ ሺ݈ܲܽݍݑ݁	ܿ݋ݑ݊ݐሻ ∗ ሺܦ݈݅ݑݐ݅݋݊	݂ܽܿݐ݋ݎሻ
ିଵ ∗ ൬ 1000	ߤ݈ݒ݋݈ݑ݉݁	݌݈ܽݐ݁݀൰ 
 Using this formula, a non-diluted 5 μl drop is countable at a minimum concentration  of 
approximately 1,000 PFU/ml.  A concentration of 103 PFU/ml would therefore be unacceptable 
as a starting phage stock in experiments, as a controlled release of bacteriophage would be under 
detection limits much of the time. When the bacteriophage has a stock of 105 PFU/ml or more, a 
5 μl drop will appear as one large clearing due to the individual plaques merging together.   
 Bacteriophage activity can also be qualitatively visualized by observing the diameter of 
the clearing, especially as a result of a delivery material containing bacteriophage solution.  We 
would expect a high bacteriophage concentration to produce a clearing with a large diameter.  
Because of the number of variables in this method, it is difficult to quantify the number of PFUs 
from the diameter of the clearing. 
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2.3 Results 
2.3.1 Concentration of Bacteriophage Stocks 
When we followed the protocol as described above, the resulting bacteriophage stocks 
showed very high activity.  Generally, the concentration of a new stock was found to be 1010.  
The maximum concentration that we observed in a new stock was 1014, while the mimimum we 
observed was 108.  The bacteriophage stocks were stored at 4°C without stabilizers.  The 
bacteriophage stocks maintained the original concentration for at least two months. 
2.3.2 Growth of Bacteriophage over Time 
We were able to create a visual representation of bacteriophage activity over time using a 
scanner in a temperature-controlled 37°C chamber.  The experiments were carried out for 24 
hours, with scans taken every 5 minutes.  
To measure the radial spread of bacteriophage activity, we placed 15 μl of bacteriophage 
suspension on a sterilized disc of 703 blotting paper obtained from VWR.  The blotting paper 
absorbed the liquid completely, such that the entire volume of liquid applied to the paper was 
transferred onto the plate. 
In early experiments, we plated the bacteriophage-loaded discs onto agar without pre-
growing the bacteria.  We found that early clearing was difficult to visualize as there was no 
contrast between bacteriophage activity and the early stages of lawn growth.  Since 
bacteriophages are known to be less effective on fully pre-grown lawns, we instead plated the 
paper discs on lawns that had been incubated for 2 hours.   
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 As seen in Figure 2.4, we loaded the paper discs with one of the following 
concentrations: 107, 108, 109, or 1010 PFU/ml.  In those plates, all of them showed some 
contamination (denoted by the dark gray area).  Two of the plates (not shown) indicated clearing 
independent of the bacteriophage-loaded discs due to condensation on the lid falling onto the 
agar and impeding bacterial growth.  However, the images do show that lower concentrations 
yield smaller clearings.  The images shown were taken after 7 hours of incubation. 
 
 We measured the distance of bacteriophage clearing on the above images, though the 
radii should be considered an approximation due to the clearing from the condensation, as well 
as the interference from the contamination.  We took 4 radius samples per paper disc, and the 
radii were measured in ImageJ.  The results are recorded in Table 2.1 and graphed in Figure 2.5. 
 
Figure 2.4 
Bacteriophage-loaded papers (black circles) on a 2-hour pre-
grown lawn.  Contamination is indicated by the dark gray masses 
around the papers.  The lawn of E.coli is shown in light gray.  
Bacteriophage clearing is indicated by the white areas.The radius 
of the clearings is indicative of the bacteriophage concentration 
relative to the other samples. 
Images taken after 7 hours of incubation. 
5 cm 
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Table 2.1 
Average Radii (mm) 
  Bacteriophage Concentration, PFU/ml 
  107  108  109  1010 
Bottom  5.48 5.39 6.88 7.06
Left  5.35 5.75 6.43 7.06
Top  4.85 6.43 7.01 6.88
Right  5.48 5.98 6.65 5.80
Average  5.29 5.89 6.74 6.76
 
 
  
 
 
 
 
 
Using the scanner, we also obtained images every 5 minutes for a span of 24 hours.  In 
Figure 2.6, discs of blotting paper were loaded with 15 μl of bacteriophages, of either 108 or 1010 
PFU/ml.  
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Figure 2.5 
Average radius of bacteriophage release from blotting paper at various concentrations.  The error is 
attributed to contamination found in the paper. 
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The radius of bacteriophage activity was measured in ImageJ and was taken at four 
points: top and bottom of the disc, as well as to the left and right.  The measurements are given in 
Table 2.2 and graphed in Figure 2.7.  The bacteriophages showed rapid growth until hour 12, 
after which the cleared area remained approximately the same size. 
 
 
 
 
 
 
 
Figure 2.6 
Scanner images of bacteriophage clearing over time. 
Discs on left contain 1010 PFU/ml concentration, discs on right contain 108 PFU/ml 
concentration.  The black circles indicate the papers.  The gray area is the lawn of 
E.coli growth, while the white area indicates cleared areas. 
Images taken at A. Time 0; B. 6 hours; C. 12 hours; D. 24 hours 
DC 
A B
3 cm 
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Table 2.2 
Radii of Activity from 108 Disc (mm)  Radii of Activity from 1010 Disc (mm) 
  Time 0  Hour 6  Hour 12  Hour 24    Time 0  Hour 6  Hour 12  Hour 24 
Bottom  0.00  1.16  2.02 2.02 Bottom  0.00 2.38  3.90 4.26
Left  0.00  1.30  2.31 2.31 Left  0.00 2.53  4.26 4.77
Top  0.00  1.16  2.24 2.24 Top  0.00 2.31  3.39 4.19
Right  0.00  2.02  4.04 4.26 Right  0.00 2.60  4.04 4.33
Average  0.00  1.41  2.65 2.71 Average  0.00 2.46  3.90 4.39
   
 
 
2.4 Conclusions 
The bacteriophage stocks that we made from the incubation of single plaques were more 
successful than those grown from older stocks.  Similarly, bacteria stocks grown from colonies 
produced by the frozen master stock were more stable and less prone to mutation than those 
grown from colonies produced by refrigerated stock.  Multiple iterations of using existing stock 
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Figure 2.7 
Graphical representation of bacteriophage activity, as measured by the distance from the edge of the paper disc to the 
edge of the cleared area, over time. 
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to make new stock eventually resulted in spotty bacteria lawns and weak plaque formation.  This 
is likely to be a result of a mutation in the bacteria than the bacteriophage, which do not adapt as 
easily. 
Bacteriophage stocks were evaluated for concentration after they were made, resulting in 
very high concentrations of 108-1014 PFU/ml.  At these concentrations, the bacteriophage stocks 
are very stable when stored at 4°C. 
When bacteriophage solution is applied to blotting paper, the resulting clearing is a 
function of the volume of solution as well as the concentration.  A blotting paper disc with a 
relatively high amount of bacteriophage solution is less dry upon plating, which helps to support 
bacteriophage activity. 
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CHAPTER 3: DELIVERY VIA POLYMER HYDROGEL 
3.1 Introduction 
 The principles of bacteriophage delivery are similar in many ways to those of drug 
delivery.  Biomaterials used for drug delivery, especially degradable materials, must be 
compatible with the body’s systems.  When treating inflammation or infections, the delivery 
material must be able to withstand both normal body chemistry, as well as the chemistry of the 
mounted immune response.  At the site of infections, the microenvironment experiences a rise in 
temperature and a decrease in pH [1]. 
 Hydrogels are a class of material that has been successful in drug delivery applications.  
Due to their wide range of polymer compositions and preparation methods, hydrogels are often 
used for controlled release, especially for local delivery [2].  Many hydrogels are made from 
naturally-derived polymers, which are the focus of this study.  We chose naturally-derived 
polymers – in the forms of polysaccharides and proteins – because they show a high degree of 
biocompatibility, both in hydrogel form and after degradation [3]. 
The main polymer that we used in this experiment was alginate.  A widely used 
biomaterial for wound healing and tissue engineering, alginate is a polysaccharide that is 
extracted from brown algae.  Alginate is a copolymer, consisting of (1,4)-linked β-D-mannuronic 
acid monomers (abbreviated as M) and α-L-guluronic acid (abbreviated as G).  The 
polysaccharide is made up of three distinct blocks: M-blocks (i.e. MMMMMM), G-blocks (i.e. 
GGGGGG), or alternating blocks (i.e. GMGMGM) [4].  As shown in Figure 3.1, the structure of 
the G-blocks is more angular and provides stiffness, while the M-blocks are more linear and 
provide flexibility [5].   
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Alginate hydrogel transitions from a viscous liquid into a gel via ion exchange.  The 
sodium ions present in the alginate solution are exchanged for the divalent ions in the ion 
crosslinker solution.  The divalent ions form bridges between monomers of the G-blocks.  The 
cross-linked regions form a three-dimensional helix shape, also called an “egg-box,” as modeled 
in Figure 3.2 [6].  When placed in lambda buffer, the calcium ions eventually exchange with the 
monovalent sodium ions in the buffer, which breaks these linkages.  When the crosslinks break, 
the bead takes in water and swells.  Eventually, the degree of crosslinking falls enough for the 
beads to dissolve completely [6]. 
 In this experiment we compared the release rates of pure alginate beads with alginate-
blend beads.  Firstly, gelatin is one of the blend polymers that we chose.  Unlike alginate, gelatin 
is a protein.  In medicine, gelatin is used as a film, in oral delivery, or in optical applications.  Its 
mechanical properties can be modified by crosslinking with small molecules like genipin [7], 
though gelatin also exhibits temperature-sensitive solidification.   
Figure 3.1
Chemical structures of alginate M-blocks, G-
blocks, and alternating blocks 
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 The second polymer we chose is collagen.  Like gelatin, collagen is a protein and can be 
modified by crosslinking either by exposure to ultraviolet light or with small molecules.  
Collagen is considered to be more biocompatible than gelatin, which is most often restricted to 
the digestive system.  In comparison, collagen may be used in nanoparticles, wound dressings, 
and tissue engineering.   In drug delivery, collagen may be tailored to the target area of the body.  
Corneal infections are often treated with collagen film, while bone formation may be stimulated 
with a collagen-bone morphogenetic protein composite.  When treating wet tissue, collagen is 
often in hydrogel form [8]. 
 Lastly, we studied chitosan hydrogel.  Like alginate, chitosan is a polysaccharide.  It is 
known for quickly responding to changes in its environment.  Chitosan polymer is especially 
sensitive to pH, as it dissolves in an acidic environment.  Like the previous polymers, it is often 
modified by grafting or crosslinking to improve its toughness and stability [9].  Chitosan has 
been successfully used in wound healing, tissue engineering, and drug delivery applications [10], 
making it a candidate for bacteriophage delivery.    
 
 
 
Figure 3.2 
Interaction of divalent calcium ion and alginate G-block  
38 
 
3.2 Experimental 
3.2.1 Materials 
3.2.1a Alginate Hydrogel 
The alginate hydrogel was made from low-viscosity alginic acid sodium salt from Alfa 
Aesar.  The alginic acid powder was dissolved in nanopure water to form a 5% solution, then 
autoclaved.  The alginate gel was left to thicken at room temperature overnight before use.  Ion 
crosslinker solutions were made from calcium chloride and barium chloride powders from J. T. 
Baker.  The salts were dissolved in a nanopure water to a concentration of 100 mMol.   
3.2.1b Gelatin Hydrogel 
For some of the experiments, alginate hydrogel was blended with one of the following: 
gelatin, collagen, or chitosan.  The gelatin was obtained from Amresco.  Gelatin powder was 
dissolved in nanopure water to form a 10% solution under gentle heat and stirring, then 
autoclaved.   The gelatin gel was stored in a 50°C water bath to prevent solidification.   
3.2.1c Chitosan Hydrogel 
The chitosan powder was obtained from TCI.  To prepare the hydrogel, we dissolved the 
chitosan in 0.5% acetic acid under gentle heat and stirring to form a 1% solution.  The solution 
was then autoclaved.  After autoclaving, genipin from Cayman Chemical Company was 
suspended in lambda buffer at a 5% concentration.  A 0.5 ml aliquot of genipin suspension was 
introduced to the chitosan solution and was gently shaken at 37°C for 2.5 hours to allow for 
crosslinking.  The crosslinking reaction produces a change in color, and the final solution turned 
a light blue color.  The crosslinked chitosan yielded a viscous liquid, which was combined with 
alginate and incubated in calcium ion solution. 
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3.2.1d Collagen Hydrogel 
A bovine achilles tendon collagen powder was obtained from Alfa Aesar.  The collagen 
powder was dissolved in 0.5% acetic acid under gentle heat and stirring to form a 1% solution.  
The solution was then autoclaved.  After autoclaving, a crosslinking agent was added to the 
hydrogel solution.  In the first trial, approximately 0.4 mg transglutaminase powder was added 
and the mixture was incubated at 37°C under shaking.  In the second trial, 0.5 ml of a 5% 
genipin suspension was added and the mixture was incubated at 37°C under shaking.  The 
resulting solution was mixed with alginate and incubated in calcium ion solution. 
The prepared gels were placed in lambda buffer to measure release kinetics.  The lambda 
buffer contains 0.58% sodium chloride from BDH, 0.02% magnesium sulfate from Fisher 
Chemical, 5% Tris buffer (1M, pH 7.5) from Alfa Aesar and 0.01% reagent-grade gelatin from 
Amresco. 
3.2.2 Experimental Design 
 Hydrogels are known for their variable degradation rates, depending on processing 
conditions.  In this experiment, we aim to compare release kinetics of pure alginate with alginate 
blends.  We chose alginate as a base polymer because of its ability to be shaped into millimeter-
scale beads, comparable in size to readily-available gel-cap medications.  The polymers were 
prepared with nanopure water (or acetic acid diluted with nanopure water, as appropriate) and 
autoclaved to reduce contamination.  The gels were prepared with water instead of 
bacteriophage-supporting lambda buffer to reduce the number of variables affecting the ion 
crosslinks. 
The alginate or alginate blend gels were mixed with bacteriophage solution with a vortex 
mixer.  The gel was then drawn up by a pipet or micropipette and dropped into the ion 
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crosslinker solution under gentle stirring.  The gel beads incubated in the ion solution for 10 
minutes.  Early experiments showed that the degradation time of alginate beads was the same for 
10- and 15-minute incubations. 
 After incubation, the ion solution was drained and the excess was removed with a sterile 
micropipette.  We used sterile tweezers to transfer the beads into either well plates or 
microcentrifuge tubes containing 1 ml of lambda buffer each.  The beads were placed in a shaker 
at 37°C.  The beads were kept at 37°C to mimic human body temperature.  We placed the beads 
under shaking to distribute the released bacteriophage throughout the buffer.  Although we aim 
to mimic human physiology through temperature and movement, we used lambda buffer in favor 
of a PBS solution because the lambda buffer is more well-known for supporting bacteriophage 
activity, which is necessary for the release solution. 
 At each time point, we saved the release solution from a set number of beads, and then 
plated those beads on an E.coli lawn.  The release solutions were serially diluted and measured 
for concentration.  The beads that were not plated were kept for subsequent time points, and their 
release solutions were discarded and replaced with fresh lambda buffer.  The new lambda buffer 
mimicked bacteriophage moving away from the hydrogel and being absorbed into the 
bloodstream.  The concentration gradient of bacteriophage was reset, increasing the driving force 
of bacteriophage to leave the hydrogel.  In addition, the new lambda buffer introduced new ions 
to the environment, which interact with the alginate’s ion crosslinkers.  The presence of these 
new ions promotes degradation of the polymer network, further stimulating bacteriophage 
release. 
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3.3 Results 
3.3.1 Effect of Crosslinker Ion 
 Calcium is commonly used as a crosslinking ion for alginate, and was used as a baseline 
for all other comparisons.  We found that calcium-crosslinked alginate beads swelled over the 
first 48 hours of incubation in buffer, after which they began to break down.  The beads then 
dissolved completely after 1 to 5 days, as shown in Figure 3.3.  The calcium-alginate beads held 
their spherical shape for most of that period of time.  The water influx that causes swelling also 
widens the bead’s pores.  It is expected that the moderate rate of swelling would also correlate 
with delayed bacteriophage release, rather than an initial burst of release.  We found that 
calcium-alginate beads delayed the release of bacteriophage by 8 to 12 hours.  The release of 
calcium-crosslinked beads is shown in Figure 3.6.  The releases shown compare two 
dispensation methods, as well as a comparison of solution storage times: 1 month storage at 4°C 
and no storage. 
 Barium is another common crosslinker for alginate.  Like calcium, barium is a divalent 
ion belonging to the alkaline earth period.  Barium-crosslinked alginate beads have a cloudy 
exterior, whereas calcium-crosslinked alginate is transparent.  Barium-alginate began to swell 
immediately, and lost its spherical shape after 6 hours of incubation in buffer.  However, the 
polymer was still in a gel state and had not dissolved into the liquid.  The barium-alginate also 
showed an initial burst of bacteriophage release.  Due to the early loss of spherical shape, the 
bacteriophages suspended in the interior of the bead were quickly exposed to the buffer 
environment.  The barium-crosslinked beads dissolved after 2 to 3 days of incubation, as shown 
in Figure 3.3.  The release of barium-crosslinked beads is shown in Figure 3.6.  Like the 
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calcium-crosslinked beads, this figure compares dispensation methods as well as release solution 
storage. 
 We also considered magnesium as a possible crosslinker.  Magnesium is a divalent ion 
that shares a period with calcium and barium.  We incubated alginate in a 100 mMol solution of 
magnesium sulfate, which is a salt consisting of a divalent cation and divalent anion.  The 
alginate did not form spheres.   
A subsequent literature search found that magnesium does not bind with alginate as 
effectively as calcium, and requires a five-fold increase in the concentration of the ion solution 
[11].  Additionally, sulfate salts are not commonly used in alginate crosslinking.  Monovalent 
chloride anions appear be preferable to divalent sulfate ions in binding the exchanged sodium 
ions, which indicates that ion exchange between the sodium ions and magnesium ions is not 
entropically favorable in this particular case.  This leads us to believe that a high concentration of 
magnesium chloride (MgCl2) may crosslink the alginate into spheres.  This hypothesis will be 
tested in future experiments. 
3.3.2 Effect of Bead Dispensation Method 
 Two methods of dispensing hydrogel into ion crosslinker solution were compared.  In the 
first, we tried cutting a 1-ml micropipette tip at the 250 μl mark, resulting in a diameter of 6 mm.  
Using this system, beads of approximately 100 μl in volume were dispensed.  However, the 
scissors used to cut the tip were thought to be a potential source of contamination, despite pre-
sterilizing the blades.  We also attempted dispensing beads via a 15-ml pipet tip.  The 15-ml 
pipet was individually sealed in a sterile container, with a tip diameter of 3 mm.  Despite the 
difference in diameter size, the 15-ml pipet dispensed beads of a similar size – approximately 
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83.3 μl – because of the hydrogel’s cohesive force when forming a drop.  In Figure 3.5, the two 
dispensation methods are compared. 
 We did not see a reduction in contamination, however.  In both cases, the beads did not 
show contamination after 21 hours of incubation, but did show a small amount of contamination 
around the bead after 24 hours. 
3.3.3 Effect of Incubation Containment 
Early alginate experiments were incubated in 1.5 ml microcentrifuge tubes.  The opening 
of the microcentrifuge tube is approximately 1 centimeter, and is tapered at the base.  We found 
that the alginate bead initially settled at the bottom of the tube, with only the upper surface area 
in contact with the free buffer.  As the bead swelled, it floated to the midsection of the 
microcentrifuge tube and was surrounded more evenly by the buffer.  The swelling of the 
barium-crosslinked beads spanned the area of the midsection, while the calcium-crosslinked 
beads gained less volume.  The barium-crosslinked beads were more obstructive to attempts to 
draw up release solution, and were often destroyed by the micropipette tip in the process. 
Subsequent experiments were performed in a 24-well plate, which is made up of 
cylindrical wells without tapering.  Each well was approximately 1.5 centimeters in diameter.  In 
this environment, the alginate beads are able to float freely in buffer.  The swelling of the 
alginate beads did not reach the diameter of the wells.  Dissolution happened more naturally in 
this environment, without a narrow boundary to limit burst, and reduced disturbance by 
micropipette tips. 
3.3.4 Sterilization Technique 
 Early experiments were performed with 2% pure alginate, which was sterilized via filter 
sterilization.  However, this was found to be an inefficient technique due to the viscosity of the 
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hydrogel.  Multiple filters were required in order to sterilize small amounts of alginate.  After 
sterilization, we found that the filtered hydrogel was easily contaminated. 
 We then attempted to autoclave the 2% alginate solution, but the solution lost a 
significant amount of viscosity.  The autoclaved 2% solution was thin enough that it did not form 
beads in calcium ion solution.  A subsequent literature search confirmed this phenomenon, 
showing that a 1% alginate solution decreased in viscosity by 78%, and a 3% alginate solution 
decreased in viscosity by 86%.  The loss in viscosity is caused by the depolymerization of 
alginate that occurs at temperatures above 100°C.  Subsequent experiments would instead begin 
with a higher concentration and thus a higher viscosity to compensate for solution thinning.  A 
5% alginate solution was autoclaved, then left to stand overnight.  The solution appeared to 
regain a small amount of viscosity after storage at room temperature.  The autoclaved alginate 
was sterilized in small amounts to prevent excessive transfer between containers, and was found 
to harbor less contamination than the filter sterilized solution. 
3.3.5 Effect of Blending with Gelatin 
The alginate:gelatin blend was made with a 5% alginate solution and 10% gelatin 
solution.  Several alginate-gelatin blends were considered.  In the first trial, we studied 25:75, 
50:50, and 75:25 alginate:gelatin blends.  The 25:75 alginate:gelatin blend dissolved upon 
incubation in the calcium ion solution, and was taken off-study.  The 50:50 and 75:25 
alginate:gelatin blends successfully formed into beads, though their shape was an ellipsoid rather 
than a sphere.  The dissolution times of the beads increased with increasing amounts of alginate, 
and are shown in Figure 3.4.  The release profiles for calcium-crosslinked and barium-
crosslinked alginate are shown in Figures 3.6 and 3.7, respectively. 
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In the second trial, we studied 33:67, 60:40, and 90:10 alginate:gelatin blends.  Each 
blend formed a bead upon incubation in the calcium ion solution.  The 33:67 blend dissolved 
very quickly, while the 60:40 alginate:gelatin blend stayed in gel form longer.  The 90:10 
alginate:gelatin blend showed a dissolution time similar to that of pure alginate.  The dissolution 
times are shown in Figure 3.4, and the release profile is shown in Figure 3.9. 
3.3.6 Effect of Blending with Collagen 
 The alginate:collagen beads were made with a 1% collagen solution, which introduces 
more water into the hydrogel mixture than the 10% gelatin hydrogel.  The dry collagen was 
obtained from bovine achilles tendon, and was a stringy and airy network rather than a powder.  
When dissolved in 0.5% acetic acid, the collagen solution appeared white and cloudy.  After 
autoclaving the solution, we attempted two different crosslinking agents: transglutaminase and 
genipin.  Following a protocol by Janine M. Orban [12], we allowed the transglutaminase 
powder to incubate in the collagen solution for 2 hours at 37°C.  However, this method did not 
crosslink the collagen, and it remained a liquid.  Subsequent mixing with alginate and exposure 
to calcium ions did not produce beads.  Further investigation into crosslinking by 
transglutaminase was not pursued for budgetary reasons. 
 In our second trial, genipin was used to crosslink collagen.  Based on a protocol by 
Shunji Yunoki [13], we incubated 0.5 ml of 5% genipin in lambda buffer and 1% collagen 
solution at 37°C under shaking, while observing periodically for a change in color.  The collagen 
was crosslinked and in a pourable state after 19 hours of incubation.  The collagen was mixed 
with alginate in a 33:67, 60:40, and 90:10 ratio of alginate:collagen.  Upon incubation, we found 
that the 33:67 and 60:40 alginate:collagen blends did not form beads, likely because of the high 
water content introduced by the collagen solution.  We continued the experiment with the beads 
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formed from 90:10 alginate:collagen.  The release of the alginate:collagen blend is found in 
Figure 3.9. 
 
3.3.7 Effect of Blending with Chitosan 
 A chitosan solution was made by dissolving chitosan powder into 0.5% acetic acid, to 
form a 1% solution.  Using the protocol described above, we incubated the chitosan solution with 
0.5 ml of 5% genipin in lambda buffer.  The crosslinking reaction reached a crosslinked, 
pourable state after 2 hours.  The chitosan was mixed with alginate quickly, as the chitosan 
tended to become sticky and immiscible if left at room temperature for more than 1 hour.  Like 
the collagen hydrogel, the chitosan was mixed with alginate in 33:67, 60:40, and 90:10 
alginate:chitosan ratios.  Again, the 33:67 and 60:40 alginate:chitosan ratios did not form beads.  
The 90:10 alginate:chitosan beads were used in this experiment. The release from these beads is 
shown in Figure 3.9. 
3.3.8 Dissolution and Release 
 
 
Figure 3.3 
Dissolution times observed in 3 iterations of alginate bead experiments.  Two iterations tested 
beads dispensed with a cut 1-ml pipette tip, while one iteration tested beads dispensed with a 15-ml 
pipet.  All other processing conditions were equal.  Error bars denote standard deviation. 
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 The dissolution times, seen in Figures 3.3, 3.4, and 3.5 were recorded for all hydrogel 
blends.  The calcium-crosslinked alginate was found to dissolve slowest, followed by the the 
90:10 and 75:25 alginate:gelatin blends.  The 33:67 alginate:gelatin and 90:10 alginate:collagen 
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Figure 3.4 
Dissolution times for 5 alginate:gelatin blend ratios 
Figure 3.5 
Dissolution for 1 trial each of 90:10 alginate:collagen and 90:10 alginate:chitosan 
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blends dissolved most quickly.  It is hypothesized that allowing the collagen to crosslink for a 
longer period of time may increase the time before dissolution.  The barium:alginate blend had 
the most consistent time before dissolution. 
 The hydrogel release graphs show a burst of release from the quick dissolving blends, 
such as 90:10 alginate:collagen and 33:67 alginate:gelatin.  The slower-dissolving blends, such 
as calcium-crosslinked alginate and 90:10 alginate:gelatin, show a more sustained release of 
bacteriophages over time, which resembles zero-order release kinetics.  In practice, the different 
release patterns are both valuable, however, depending on the infection site and severity.  A 
burst-release would be beneficial for a severe infection in the stomach, while a slower release 
may be able to stay gelled long enough to reach the intestine. 
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Figure 3.6 
Cumulative bacteriophage release profile of calcium-crosslinked alginate beads.  The beads show a 
variable dissolution time, and a relatively consistent release.  Error bars indicate standard 
deviation. 
1.0E+00
1.0E+01
1.0E+02
.0E+03
.0E+04
.0E+05
.0E+06
.0E+07
1.0E+08
0 20 40 60 80 1 0 20 0
Ba
ct
er
io
ph
ag
e R
el
ea
se
d (
PF
U
/m
l)
Time (Hours)
Micropipette‐Dispense Pipet‐Dispensed
49 
 
 
 
 
1.0E+00
1.0E+01
1.0E+02
1.0E+03
1.0E+04
1.0E+05
1.0E+06
1.0E+07
1.0E+08
1.0E+09
0 10 20 30 40 50 60 70 80
Ba
ct
er
io
ph
ag
es
 Re
le
as
ed
 (P
FU
/m
l)
Time (hours)
1‐Month Stored Release Pipet‐dispensed Micropipette‐dispensed
Figure 3.7 
Cumulative bacteriophage release profile of barium-crosslinked alginate.  Release begins earlier 
than calcium-crosslinked beads, and release is relatively consistent until dissolution after a small 
initial burst.  Error bars indicate standard deviation. 
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3.3.9 Swelling Calculations 
 The rate of bacteriophage release appears to be dependent on the degree of swelling, as 
the increased volume fraction of water in a gel widens the polymer pores.  Hydrogel swelling can 
be calculated by comparing the beginning volume with the final volume.  The volumes were 
estimated by imaging the beads with a scanner, measuring the bead diameters with ImageJ, and 
using the results to calculate volume.  The swollen volume was measured using the timepoint 
before the bead lost its shape.  After calculation, we found the extension ratio (Figure 3.10). 
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The term λ denotes the extension ratio, which can be applied to any of the Cartesian 
directions.  In this case, the hydrogel is non-directional and we can assume that the extension 
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Figure 3.9 
Cumulative release profile of alginate:chitosan and alginate:collagen blends.  Alginate:collagen 
dissolved quickly with a burst of release, while alginate:chitosan dissolved slowly and showed a 
delayed onset of release.  In each case, total bacteriophage activity decreased by 1-3 orders of 
magnitude.  Error bars indicate standard deviation. 
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ratio is equal in all directions.  The initial and final volumes can also be used to find the volume 
fraction of polymer in the swollen hydrogel, indicated as φ (Figure 3.11).   
ܸ
଴ܸ
ൌ 	 1߮ 
  
Polymers with a high extension ratio and low volume fraction of polymer in a swollen 
state experienced the most swelling.  Thus, these polymers tend to release bacteriophages in a 
quick burst, as the polymer strands that retain the bacteriophages form wider pores.  Polymers 
that had a low extension ratio tended to release bacteriophages more steadily. 
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Figure 3.10 
Extension ratio of polymers tested.  The stars indicate polymer blends that 
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The high error values of the polymer volume fraction can be attributed to the different 
burst points of the hydrogel beads, as well as the fact that different beads were measured at each 
timepoint.  The relatively low values of the extension ratio are a result of the cube root of the 
volume ratio, which reduced the magnitude of error. 
 
3.3.10 Other Hydrogels Considered 
 There were two other hydrogels considered for this study.  The first is hyaluronic acid, 
which is a naturally-derived polysaccharide similar to alginate.  Both hyaluronic acid and 
alginate are copolymers containing guluronic acid monomers, with different chirality.  Current 
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Figure 3.11 
Swollen volume fraction of polymer in hydrogels tested.  The stars indicate 
polymer blends that demonstrated highest burst release.  Error bars indicate 
standard deviation. 
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applications of hyaluronic acid include drug delivery, wound dressing, and tissue engineering 
(Yi).  
 We attempted to crosslink hyaluronic acid hydrogel by precipitating sodium hyaluronate 
in methacrylic anhydride, adjusting the pH to 8 using sodium hydroxide.  The amount of sodium 
hydroxide to be added was calculated, but the amount expected to adjust the pH was found to be 
insufficient to change the color of the Neutral Red indicator.  We later found that the indicator 
used was faulty, and the hyaluronic acid hydrogel was no longer considered. 
 The second hydrogel considered was sodium polyacrylate, which is a self-crosslinking 
synthetic polymer.  Sodium polyacrylate gels upon exposure to water under stirring.  A 100 ml 
sample of 5% sodium polyacrylate solution gelled within 5 minutes of stirring.  The gel was not 
able to be shaped, and incubation of sodium polyacrylate gel in lambda buffer did not produce a 
release solution.  In fact, the sodium polyacrylate gel had absorbed the lambda buffer.  The 
sodium polyacrylate hydrogel was abandoned because we hypothesized that it would not release 
bacteriophages into a solution efficiently. 
3.3.11 Future Work 
 These experiments demonstrated release into lambda buffer, which is a supportive 
environment for bacteriophages.  Future experiments performed in an acidic solution would 
better predict the outcome of bacteriophage release and survival.  While bacteriophages are not 
stable in acidic environments, early bacteriophage experiments showed activity when 
administered orally alongside a sodium bicarbonate solution to neutralize acidity in the stomach.  
A future experiment can take these findings into account by testing bacteriophage release into a 
neutralized simulated gastric fluid solution. 
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 Additional experiments with alginate blended with collagen or chitosan would also be 
beneficial, to further explore varying degrees of crosslinking and its effect on bacteriophage 
release.  In theory, a collagen or chitosan hydrogel that has been loaded with bacteriophage and 
tightly crosslinked could be mixed with an alginate-bacteriophage solution and exposed to 
calcium chloride.  A two-phase release could be visualized upon the early breakdown of alginate, 
followed by a secondary dissolution of collagen or chitosan.  In addition, magnesium can be 
explored as a possible crosslinking ion for alginate hydrogel. 
3.4 Conclusions 
 Alginate-based hydrogels show great promise as delivery systems for bacteriophages.  
Controlling the rate of bacteriophage release can determine where the bacteriophages will be 
released in the digestive tract.  This can be done by blending alginate with other hydrogels in 
varying ratios.   
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CHAPTER 4: DELIVERY VIA POLYANHYDRIDE MICROPARTICLES 
4.1 Introduction 
Besides oral delivery, bacteriophages may also be introduced to the body through the 
nasal mucosa.  Nasal treatments are a non-invasive way to target the respiratory system, or 
distribute the drug systemically through the bloodstream.  However, effectiveness of nasal 
delivery depends on the type of drug selected.  As mentioned in section 1.6.2 of Chapter 1, 
bacteriophages can be considered to be large protein-based entities, ranging in length from 100-
200 nm.  Polar particles of high molecular weight have been shown to be the most difficult to 
cross the mucosal membrane [1], therefore a delivery vehicle must be used in conjunction with 
the bacteriophages. 
 For peptide and protein-based drugs, bioavailability after nasal application is often less 
than 1%.  Since many of these drugs are not readily absorbed through the mucosal membrane, 
the excess is either degraded enzymatically or eliminated by the mucociliary clearance process 
within approximately 20 minutes.  To improve the absorption of high-molecular-weight, polar 
drugs, there are approaches to consider: chemical modification, application of enzyme inhibitors, 
inclusion of absorption promoters like surfactants and bile salts, and encapsulation in a polymer 
microparticle [2].  In the case of bacteriophage therapy, chemical modification is not an option.  
As mentioned in 1.6.2 of Chapter 1, enzyme inhibitors and absorption promoters tend to damage 
the mucosal membrane [1].  Polymer encapsulation is the best choice for effective bacteriophage 
delivery. 
 Unlike the hydrogels of the previous chapter, polymer microparticles are a dry 
microenvironment, which can adversely affect the stability of bacteriophages.  A study of 
bacteriophages against Staphylococcus aureus encapsulated in poly(lactic-co-glycolic acid), or 
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PLGA, found that bacteriophage activity tapered off after one week in dry storage.  This result 
was seen at storage temperatures of both 4°C and 22°C.  However, bacteriophage activity can be 
retained in dry conditions with the addition of stabilizers.  The most common, non-immunogenic 
stabilizers include trehalose, sucrose, and polyethylene glycol (PEG) [3]. 
 In this study, the stabilizing effects of trehalose were considered.  Trehalose is an 
osmolyte, and preserves the activity of bacteriophages (and proteins) by stabilizing labile 
proteins in a dry state, as well as acting as a water substitute through hydrogen bonding.  Despite 
the weak interaction with the proteins that make up the bacteriophage, trehalose is found to be 
inert towards the bacteriophage.  The stabilizing effects of trehalose are also seen in high-
pressure environments, like microparticle formation, in which the bacteriophages’ protein 
capsids and tails are susceptible to pressure denaturation [4].   
 Effective absorption of bacteriophages not only depends on survival in a dry state, but 
also promotion of particle internalization.  The bacteriophage treatment will ideally be absorbed 
in the same manner as the infectious agent, while avoiding an immune response.  In this case, 
polyanhydride microparticles are an ideal delivery vector due to their biocompatibility, 
degradability, and hydrophobic nature [5]. 
 The polyanhydride microparticle is able to mimic a pathogen by activating the body’s 
innate immune system.  The immune response is mounted when a pathogen-associated molecular 
pattern (PAMP) is detected by the pattern recognition receptors (PRRs) on an antigen-presenting 
cell (APC), located among epithelial cells [6].  An example of a PAMP is the lipopolysaccharide, 
or LPS, found on E.coli cells [5].  Specifically, LPS interacts with Toll-like receptors (TLRs), 
among other PRRs.  In the case of polyanhydride microparticles, the hydrophobic nature of the 
polymer mimics PAMPs, which are often hydrophobic as well.  Upon interaction with PRRs, the 
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microparticle is internalized by the dendritic cell, either by phagocytosis or endocytosis, 
depending on polymer chemistry.  The polyanhydride then degrades, releasing bacteriophages.   
 One possible application for bacteriophage-loaded microparticles is in the treatment of 
tuberculosis.  The disease is caused by the presence of Mycobacterium tuberculosis in the 
alveolar macrophages, or AMs, which is a type of APC.  This type of infection is known as 
delayed type hypersensitivity.  Upon internalization by the AM, bacteriophages released from the 
cell would target the M. tuberculosis bacterium immediately.  A nasal bacteriophage treatment 
would target the lungs directly, as opposed to systemic oral drug delivery treatments used 
currently.  Systemic treatments rely on high doses of drug to reach the alveoli, which can cause 
several side effects in various physiological systems [7].  Nasal bacteriophage delivery, on the 
other hand, is a targeted method of delivery using a highly specific biological entity, which is a 
promising combination for fast, effective recovery. 
4.2 Experimental 
4.2.1 Materials 
 The polyanhydride microparticles tested are copolymers with varying ratios, consisting of 
two of the following monomers: sebacic acid (SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH) 
and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG).  The structures of these monomers 
Figure 4.1 
Polyanhydride monomer chemical structures.  Clockwise from top left: SA, CPH, 
and CPTEG. 
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are shown in in Figure 4.1.  The polymers used for microparticle formation were synthesized in 
Balaji Narasimhan’s lab using methods outlined in literature [8].   
 Degradation rates of polyanhydrides can be controlled by copolymerizing monomers of 
separate chemistries.  For example, monomers of aliphatic chemistries (such as SA) degrade 
relatively quickly, because water molecules are able to access and hydrolyze the anhydride 
bonds.  In contrast, aromatic monomers (such as CPH) have less accessible anhydride bonds due 
to the adjacent aromatic ring.  These polymers require much more time to degrade [9].  The 
CPTEG monomers degrade through a different mechanism than that of SA and CPH.  As seen in 
Figure 4.1, CPTEG contains a region made up of ethylene glycol that is more accessible than the 
anhydride bonds.  Water molecules are able to hydrolyze the ethylene glycol region quickly, 
precluding the necessity of hydrolyzing the anhydride bonds [8]. 
 Hydrolysis of anhydride bonds produces dicarboxylic acid by-products [9].  The 
degradation products from SA, CPH, and CPTEG have been found to be non-toxic and non-
immunogenic. However, dicarboxylic acids tend to lower the pH of the surrounding 
microenvironment.  The most acidic polyanhydride used in the microparticles was SA, which 
upon degradation lowers the pH to 4.2.  The by-products of CPH lower the microenvironmental 
pH to 5.5.  To compare, the by-products of the commonly-used poly(lactic acid-co-glycolic 
acid), or PLGA, lower the microenvironmental pH to 2 [8].  Since bacteriophages lose activity in 
highly acidic environments, the polyanhydrides SA, CPH, and CPTEG are therefore better 
choices in this application.  
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4.2.2 Experimental Design 
4.2.2a Microparticle Formation 
There are three main methods of microparticle formation: precipitation, double emulsion 
in water/oil/water, and spray-drying.  We attempted precipitation of 20:80 CPTEG:CPH by 
dissolving the polymer in chloroform and precipitating the particles in a 1:80 excess of pentane 
at -20°C.  We found that the size of the resulting microparticles was less than 1 μm in diameter, 
which is below our target size of 1-5 μm in diameter.  Due to the failure of precipitation to form 
the desired microparticle size, we opted to investigate spray-drying rather than emulsion, as 
spray-drying tends to produce larger particles.  We verified that spray-dried 20:80 CPTEG:CPH 
microparticles were the correct size through SEM.  All subsequent microparticles were produced 
by spray-drying. 
 The spray-dryer used is the model Buchi B-290 mini spray-dryer, as shown in Figure 4.2 
[10].  We began by spray-drying a control of bacteriophage suspension without polymer in order 
to obtain a control of bacteriophage activity rentention without polymer.  The bacteriophages 
Figure 4.2 
Schematic of Buchi B-290 spray-dryer.  Our phage-polymer solution was mixed on a 
stir plate before being heated and introduced to the drying chamber.  The gas used in 
the drying chamber was argon. 
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were suspended in lambda buffer.  The aqueous nature of the solvent required the spray-dryer to 
run at 80-85°C to ensure appropriate evaporation.  The bacteriophages saw a drop in activity of 5 
orders of magnitude, i.e. from 1010 PFU/ml before spray-drying to 105 PFU/ml after spray-drying 
and reconstitution. 
 To prepare microparticles of polymer and bacteriophage, the hydrophobic raw polymer 
was first dissolved in chloroform, after which the bacteriophage was added.  With this solution, 
the spray-dryer was run at 40°C to reflect the lower liquid-gas transition temperature of 
chloroform.  All other settings remained the same.  A white powder was produced, which 
adhered to the cyclon and holding vial.  Due to the low glass-transition temperature of CPTEG-
rich polymers, the microparticles were removed from the cyclon and the vial in a walk-in 
refrigerator held at 4°C. 
4.2.2b Bacteriophage preparation 
 To produce spray-dried microparticles, the encapsulating polymer was dissolved in 
chloroform as it is unstable in water.  The bacteriophages are stored in lambda buffer, but are 
stable in chloroform for a short amount of time.  To evenly distribute bacteriophage in the 
polymer solution, two methods were investigated: lyophilization (freeze-drying) or use of a 
surfactant.   
 We found that lyophilization reduced the bacteriophage activity by 4 orders of 
magnitude, i.e. a sample with an activity of 1010 PFU/ml initially showed activity of 106 PFU/ml 
after lyophilization and reconstitution.  These results were found with bacteriophages originally 
in lambda buffer and reconstituted in sterilized water, as the lambda buffer salts were assumed to 
be present in the resulting freeze-dried pellet after lyophilization. 
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 To prevent an initial drop in bacteriophage activity before spray-drying, surfactants were 
also considered.  The surfactant Tween-20 was mixed with bacteriophage solution, after which 
we evaluated bacteriophage activity.  There was no reduction in bacteriophage activity found in 
the bacteriophage-Tween-20 mixture.  In subsequent experiments, we chose to introduce an 
aqueous surfactant-bacteriophage solution to the polymer-chloroform solution before spray 
drying. 
 Early experiments were performed with both T4 and T7 bacteriophages.  Since spray-
drying subjects the bacteriophages to high shear stresses, we noted that T7, the smaller 
bacteriophage, may fare better than a longer bacteriophage, T4.  We hypothesized that T4 may 
become inactivated during spray-drying due to damage to its thin tail.  In later experiments, we 
performed trials on batches of T7 bacteriophages only, with the intention of expanding the scope 
to T4 bacteriophages if successful.  The use of trehalose as a stabilizer was also considered.  As 
mentioned in section 4.1, trehalose shows a stabilizing effect in dry environments.  We 
hypothesized that the trehalose may lessen the chance of bacteriophage inactivation by pressure 
denaturation. 
4.3 Results 
Three formulations of polymer were tested for bacteriophage release: 20:80 
CPTEG:CPH, 15:85 CPTEG:CPH, and 20:80 CPTEG:SA.  With the 15:85 CPTEG:CPH 
formulation, we tested the effectiveness of 1% w/v trehalose in the bacteriophage stock. 
4.3.1 20:80 CPTEG:CPH 
Microparticles of 20:80 CPTEG:CPH were spray-dried in three batches.  The first batch 
was a blank control made with sterilized water instead of bacteriophage solution.  The second 
batch was made with a 1012 PFU/ml T4 bacteriophage stock diluted to 1011 with sterilized water.  
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The third batch was made with a 1011 T7 bacteriophage stock diluted to 1010 with sterilized 
water.  The aqueous bacteriophage phase was mixed with Tween-20 surfactant, then stirred into 
the polymer-chloroform phase.  The mixture was kept under stirring during the spray-dry 
process. 
The total amount of bacteriophages in the pre-spray-dried solution was calculated as 
follows: 
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After the microparticles were obtained from the spray-dryer, we divided each batch into 
two groups: a slow-release group and a dry storage group.  The slow release group was kept in 
lambda buffer at 37°C under shaking.  At various timepoints, the lambda buffer was removed to 
count the amount of bacteriophages released, and the microparticles were resuspended in new 
buffer.  The dry storage group was kept at 4°C in the refrigerator.  At various timepoints, a 
sample was dissolved in chloroform, which breaks down the polyanhydride to release the 
bacteriophage.  A sample of chloroform was then mixed with buffer to encourage the movement 
of bacteriophages into the aqueous phase to be counted.  The microparticles were also imaged 
with scanning electron microscopy (SEM).  The SEM images are seen in Figure 4.3. 
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Our first slow release sample was taken 2 hours after spray-drying.  We found that the T7 
bacteriophages had a higher initial activity than T4, as seen in Figure 4.4.  The dry storage 
samples showed activity at the initial timepoint, as well as after 2 and 5 days of storage.  When 
plated, the storage samples from day 2 showed contamination that was not eradicated upon 
chloroform exposure.  On day 5, the T4 storage sample showed an activity of 104 PFU/ml, while 
the T7 storage sample showed an activity of 103 PFU/ml.  From 6 days onward, the storage 
samples showed no activity.  The study was concluded after 28 days. 
Figure 4.3 
SEM images at 5,000x magnification of 20:80 CPTEG:CPH microparticles containing.  A: blank control.  B: T4-containing C: 
T7-containing. 
A 
B C
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The 20:80 CPTEG:CPH experiment was conducted with one slow-release sample.  
Future experiments with multiple samples will be performed for more robust release data.  
Additional error was introduced in the bacteriophage stocks themselves, which were grown from 
existing stock rather than an individual plaque.  The result of this improper growth technique is 
irregularly-sized plaques that tended to be larger than expected.  This problem was rectified in 
later experiments. 
4.3.2 15:85 CPTEG:CPH 
 The first iteration of 15:85 CPTEG:CPH microparticles were created using the same 
method as described above.  Instead of separating slow release and dry storage samples, the 
microparticles were divided into 16 microcentrifuge tubes for bacteriophage-containing 
microparticles and 8 control tubes for slow release experiments.  The microparticles were again 
imaged under SEM, as seen in Figure 4.5.  In this experiment, only T7 bacteriophages were used.  
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Figure 4.4 
Release of T4 (“T4”) versus initial amount of T4 spray-dried (“Total T4”), compared to release of T7 
(“T7”) versus the initial amount of T7 spray-dried (“Total T7”).  The initial drop is lower for T7, but the 
drop over time is higher.  The T4 bacteriophage is released more gradually. 
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At each timepoint, the release solution was removed and the microparticles were washed with 
lambda buffer.  New lambda buffer was then added for incubation.  One of the samples was 
diluted to a countable level, and was assumed to reflect the release of all microparticle samples.  
At two timepoints per week, two T7-containing samples and one control sample were dissolved 
in chloroform to evaluate the amount of bacteriophage remaining in the microparticle sample.  
This test was known as a quick release. 
 At the initial timepoint, about 30 minutes after microparticle formation, all samples 
showed bacteriophage activity, althought the quick release performed after the removal of 
lambda buffer showed no activity.  The counted sample was measured to have a concentration of 
approximately 105 PFU/ml.  At the next timepoint 2 hours later, 5 of the 14 bacteriophage-
containing samples showed activity of approximately 103 PFU/ml.  No activity was seen in the 
slow release or quick release samples until the timepoint on day 5. 
 When a timepoint was taken 5 days after microparticle formation, a contaminant was 
found in the control samples, which showed strong bactericidal activity.  The contaminant did 
not show bacterial growth, and appeared to be either bacteriophage presence or a bactericidal 
chemical.  Of the bacteriophage-containing microparticles, 9 of the 10 samples showed a 
Figure 4.5 
SEM images of 15:85 CPTEG:CPH at 5,000x magnification.  A: blank control. B: T7-containing 
microparticle. B
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countable level of activity.  We hypothesize that a smaller amount of contaminant was in the 
bacteriophage-containing samples than the blank samples.  In the day 6 sample, we found that 
the activity in control samples persisted while the bacteriophage-containing samples again 
showed countable activity of approximately 103 PFU/ml.  We filter-sterilized the subsequent 
samples and found that the control-sample contaminant was still present at day 7, absent at day 
10, and present again at day 14.  The bacteriophage-containing microparticles showed activity of 
103 PFU/ml in 2 of the 8 remaining samples.  The quick release timepoints measured within 
these time frames showed no activity.  All further samples, taken until day 28, were found to 
have no activity. 
 
 A second iteration of 15:85 CPTEG:CPH was tested using a bacteriophage solution with 
1% w/v trehalose as a stabilizer.  This experiment was set up much like the previous iteration, 
although 8 tubes of T7-microparticles were used instead of 16 due to limitations in the amount of 
raw polymer available. 
 An initial timepoint was performed at about 30 minutes after microparticle formation.  
The release into lambda buffer showed activity in all bacteriophage-containing samples of 
approximately 103 PFU/ml.  The quick release, performed after the lambda buffer exposure, 
showed no activity.  All subsequent timepoints, taken until day 28, showed no activity.  
4.3.3 20:80 CPH:SA  
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 Early experiments with 20:80 CPH:SA showed that it does not support bacteriophage 
activity well due to the acidity of the SA by-products.  In this study, we prepared microparticles 
with bacteriophage only, without stabilizers.  The microparticles were prepared in three batches, 
similar to the 20:80 CPTEG:CPH study: a blank control, T4-containing, and T7-containing 
microparticles.  The resulting powder was divided into two microcentrifuge tubes per 
bacteriophage type.  Some of the microparticles were imaged under SEM, shown in Figure 4.6. 
 
The first timepoint was taken 2 hours after microparticle formation.  Both T4 samples 
showed no activity into lambda buffer.  The T7 samples showed activities of 102 and 103 PFU/ml 
in each respective tube.  The control did not show activity.  Subsequent timepoints over 7 days 
showed no activity.  After 8 days, we amplified the lambda buffer release solutions for a 
qualitative assessment of bacteriophage activity.  To amplify bacteriophage activity, we placed 
10 μl of the release solution in 90 μl of bacteria solution.  The mixture was incubated for 12 
hours at 37°C.  The samples were then centrifuged to separate the bacteria from the 
bacteriophages.  The bacteriophage-containing samples were then plated.  Bacteriophage activity 
was present at 2 hours, 3 days in the T4-containing samples, 4 days in one T7-containing 
Figure 4.6 
SEM images of 20:80 CPH:SA.  A: blank control.  B: T4-containing microparticles. C: T7-containing microparticles.  The 
blank control polymer did not form into microparticles, unlike the T4- and T7-containing polymer mixtures.  We hypothesize 
that this may be because of the bacteriophages acting as nucleation points during microparticle formation. 
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samples, and 5 days in one T4-containing sample.  These results were not able to be quantified, 
but rather were used as a qualitative analysis. 
4.3.4 Future Work 
 The CPTEG:CPH blends appear to be the best polymer type for supporting bacteriophage 
activity.  The 20:80 CPTEG:CPH blends show the longest-term support for bacteriophage 
activity, at 5 days.  A wider-scale study with more samples will be performed to test the 
repeatability of these findings.  In addition, a trehalose stabilizer will be added to the 20:80 
CPTEG:CPH blends to determine whether bacteriophage activity can be retained during spray-
drying.  In addition, all subsequent studies will be performed with a chloroform quick release on 
a sample of freshly-made microparticles, without prior exposure to lambda buffer, for a better 
estimate of bacteriophage activity retained after encapsulation.  
4.4 Conclusions 
 While the 20:80 CPTEG:CPH experiment appeared to be the most promising of the 
chemistries studied, additional iterations of the experiment must be conducted.  The 15:85 
CPTEG:CPH formulation showed initial bacteriophage release both with and without the 
trehalose addition.  The 20:80 CPH:SA microparticles released bacteriophage in the smallest 
amounts, likely because of the acidity of the microenvironment that results from SA degradation.   
4.5 Acknowledgments 
 The authors would like to thank the laboratory of Balaji Narasimhan for graciously 
allowing us access to their spray-dryer.  The authors gratefully thank Tim Brenza for the 
synthesis of raw polymer for use in this study, as well as guidance in microparticle synthesis.  
4.6 References 
[1] Illum L. Nasal drug delivery-possibilities, problems and solutions. Journal of Controlled 
Release. 2003;87:187-98. 
70 
 
[2] Ozsoy Y, Gungor S, Cevher E. Nasal Delivery of High Molecular Weight Drugs. Molecules. 
2009;2009:3754-79. 
[3] Puapermpoonsiri U, Ford SJ, van der Walle CF. Stabilization of bacteriophage during freeze 
drying. International Journal of Pharmaceutics. 2010;389:168-75. 
[4] Kaushik JK, Bhat R. Why Is Trehalose an Exceptional Protein Stabilizer? The Journal of 
Biological Chemistry. 2003;278:26458-65. 
[5] Petersen LK, Ramer-Tait AE, Broderick SR, Kong C-S, Ulery BD, Rajan K, et al. Activation 
of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride 
nanoparticle adjuvants. Biomaterials. 2011;32:6815-22. 
[6] Carrillo-Conde BR, Ramer-Tait AD, Wannemuehler MJ, Narasimhan B. Chemistry-
dependent adsorption of serum proteins onto polyanhydride microparticles differentially 
influences dendritic cell uptake and activation. Acta Biomaterialia. 2012;8:3618-28. 
[7] Parikh R, Dalwadi S, Aboti P, Patel L. Inhaled microparticles of antitubercular antibiotic for 
in vitro and in vivo alveolar macrophage targeting and activation of phagocytosis. Journal of 
Antibiotics. 2014. 
[8] Lopac SK, Torres MP, Wilson-Welder JH, Wannemuehler MJ, Narasimhan B. Effect of 
Polymer Chemistry and Fabrication Method on Protein Release and Stability from 
Polyanhydride Microspheres. Journal of Biomedical Materials Research Part B, Applied 
Biomaterials. 2009;91:938-47. 
[9] Ron E, Mathiowitz E, Mathiowitz J, Domb A, Langer R. NMR Characterization of Erodible 
Copolymers. Macromolecules. 1991;1991:2278-82. 
[10] Chavarri M, Maranon I, Villaran MC. Encapsulation Technology to Protect Probiotic 
Bacteria2012. 
 
 
 
 
 
71 
 
CHAPTER 5: SUMMARY AND CONCLUSIONS 
 Historically, bacteriophages have been shown to be effective in treating bacterial 
infections as well as acting as prophylactic measures.  Recently, antibiotics have fallen out of 
favor due to an increasing prevalence of antibiotic-resistant bacteria, as well as difficulty in 
developing new formulations of antibiotics.  Bacteriophages are a remarkable alternative to 
antibiotics due to their ubiquity, specificity, and variability in mechanisms for bacterial lysis. 
 Effective delivery of bacteriophages involves maintaining lytic activity, as well as 
tailoring a release rate appropriate to a particular situation.  Delivery methods may be engineered 
to release bacteriophages in a burst for rapid treatment of a local infection, or may be released at 
a low, steady level for prophylactic effect.  For these uses, we look to biodegradable polymers 
for controlled release of bacteriophages. 
 Hydrogels are a class of biomaterial commonly used in controlled release studies.  They 
are easily modified for stability in various environments through crosslinking.  In this study, we 
have shown that hydrogels are able to support bacteriophage activity, and are able to release 
bacteriophages into a buffer solution both in a burst or steady output, depending on the method 
of blending and crosslinking.   
 Polymer microparticles are another possible vector for bacteriophage delivery.  The 
microparticles are commonly applied to the nasal mucosa, either for systemic release or to 
directly treat pulmonary infections.  The polyanhydride microparticles, specifically the 
CPTEG:CPH copolymers, have been shown to support bacteriophages for a short amount of 
time, releasing them in an initial burst.  Future experiments will be performed to investigate the 
possibility of longer-term release. 
